Financials Bellevue Life Sciences Acquisition Corp.
Equities
BLAC
US0791741087
Investment Holding Companies
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.73 USD | -.--% | -.--% | +2.19% |
Valuation
Fiscal Period: December | 2023 |
---|---|
Capitalization 1 | 95.08 |
Enterprise Value (EV) 1 | 95.13 |
P/E ratio | 210 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | - |
EV / FCF | 123,789,652 x |
FCF Yield | 0% |
Price to Book | -15.1 x |
Nbr of stocks (in thousands) | 9,055 |
Reference price 2 | 10.50 |
Announcement Date | 4/17/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net sales | - | - | - | - |
EBITDA | - | - | - | - |
EBIT 1 | -0.0238 | -0.003308 | -0.0354 | -1.831 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.0238 | -0.003308 | -0.0354 | 0.9446 |
Net income 1 | -0.0238 | -0.003308 | -0.0354 | 0.4038 |
Net margin | - | - | - | - |
EPS 2 | -0.0190 | -0.002205 | -0.0236 | 0.0500 |
Free Cash Flow | - | 0.2736 | -0.273 | 0.7685 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | 190.33% |
Dividend per Share | - | - | - | - |
Announcement Date | 3/12/21 | 4/29/22 | 3/31/23 | 4/17/24 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net Debt 1 | 0.24 | 0.41 | 1.09 | 0.06 |
Net Cash position 1 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | 0.27 | -0.27 | 0.77 |
ROE (net income / shareholders' equity) | - | 710% | 179% | -20.5% |
ROA (Net income/ Total Assets) | - | -0.4% | -2.29% | -6.05% |
Assets 1 | - | 0.8223 | 1.545 | -6.679 |
Book Value Per Share 2 | 0 | -0 | -0.0300 | -0.6900 |
Cash Flow per Share 2 | 0.0400 | 0 | 0.0800 | 0 |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 3/12/21 | 4/29/22 | 3/31/23 | 4/17/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+2.19% | 60.33M | |
+180.51% | 8.67B | |
+2.29% | 983M | |
+41.91% | 883M | |
+26.17% | 825M | |
+1.92% | 665M | |
+9.52% | 664M | |
-.--% | 600M | |
+9.17% | 530M | |
-.--% | 500M |
- Stock Market
- Equities
- BLAC Stock
- Financials Bellevue Life Sciences Acquisition Corp.